Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

We apply our expertise in science and innovation to society’s biggest health challenges. Responsibility is a core part of our business strategy.
Company Growth (employees)
Basel, CH
Size (employees)
118,393 (est)
Novartis was founded in 1996 and is headquartered in Basel, CH

Key People at Novartis

Joseph Jimenez

Joseph Jimenez

Chief Executive Officer
Harry Kirsch

Harry Kirsch

Chief Financial Officer
Paul van Arkel

Paul van Arkel

Head of Corporate Strategy and Healthcare Systems
Peter Elam

Peter Elam

Head of Internal Audit
Erwin Vanhaecke

Erwin Vanhaecke

Head Novartis Group Quality
Michael Willi

Michael Willi

Group Head of Communications
Felix Ehrat

Felix Ehrat

Group General Counsel
Richard Francis

Richard Francis

CEO, Sandoz
Andre Wyss

Andre Wyss

President, Novartis Operations Country President for Switzerland
Juergen Brokatzky-Geiger

Juergen Brokatzky-Geiger

Global Head, Corporate Responsibility for Novartis
Michael Ball

Michael Ball

CEO, Alcon
James Bradner

James Bradner

President, Novartis Institutes for BioMedical Research
Paul Hudson

Paul Hudson

CEO, Novartis Pharmaceuticals
Bruno Strigini

Bruno Strigini

CEO, Novartis Oncology
Steven Baert

Steven Baert

Head of Human Resources

Novartis Office Locations

Novartis has offices in Basel, East Hanover, New York, Wehr and in 2 other locations
Basel, CH (HQ)
Forum 1, Novartis Campus
Tokyo, JP
Toranomon Hills, Mori Tower, 1 23 1, Toranomon, Minato Ku
Beijing, CN
14th Floor, China World Tower 2, No.1 Jian Guo Men Wai Avenue, Chao Yang District
Wehr, DE
Oeflingerstrasse 44
New York, US
230 Park Avenue, 21st Floor
East Hanover, US
1 Health Plazam, Bldg. 101

Novartis Data and Metrics

Novartis Financial Metrics

Novartis's revenue was reported to be $48.5 b in FY, 2016 which is a 2% decrease from the previous period.

Revenue (FY, 2016)

48.5 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

31 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

6.7 b

Market capitalization (31-Jan-2017)

175.5 b

Closing share price (31-Jan-2017)

Novartis's current market capitalization is $175.5 b.
USDFY, 2014FY, 2015FY, 2016


53.6 b49.4 b48.5 b

Revenue growth, %


Cost of goods sold

17.3 b17.4 b17.5 b

Gross profit

36.3 b32 b31 b

Gross profit Margin, %


Sales and marketing expense

12.4 b11.8 b12 b

R&D expense

9.1 b8.9 b9 b

General and administrative expense

2.6 b2.5 b2.2 b

Operating expense total

25.2 b24 b23.6 b

Interest expense

(704 m)(655 m)(707 m)

Interest income

(31 m)(454 m)(447 m)

Net Income

10.3 b17.8 b6.7 b
USDFY, 2015FY, 2016

Cash From Operating Activities

12.1 b11.5 b
USDY, 2016


411.2 k

Novartis Operating Metrics

Y, 2015Y, 2016

Patients Reached

972 m965 m

Projects Entering Development Pipeline


Major Submissions (US, EU, JP)


Major Approvals (US, EU, JP)


Phase III Trials


US FDA Breakthrough Therapy Designations


Novartis Market Value History

Novartis Revenue Breakdown

Novartis Job Categories

Novartis Median Salaries

Source: 453 public H-1B filings from Novartis

Novartis Online and Social Media Presence

Novartis News and Updates

Novartis Company Life and Culture

You may also be interested in